The following mechanisms of action were considered in the selection of small molecules: (1) to downregulate CD27, PD1, and PDL1 expression; (2) to inhibit proliferation genes that had a significant impact in 100% of tested NSCLC cell lines in CRISPR-Cas9 and RNAi assays; (3) to maintain a high expression of survival protection genes that expressed higher in the long survival patient group; (4) to downregulate the expression of survival hazard genes that expressed higher in the short survival patient group. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.